fish vaccine market is estimated to witness high growth, owing to rising fish farming activities & increasing fish diseases
fish vaccine market is estimated to be valued at USD 375.1 Mn in 2024, exhibiting a CAGR of 9.1% over the forecast period 2024-2031. Increasing fish farming activities worldwide along with rising prevalence of various viral and bacterial diseases in fish can drive the market growth. Furthermore, advancements in vaccine development technologies can also drive the market growth
Market Dynamics:
Rising adoption of intensive fish farming practices to meet growing demand for fish protein can lead to increased risk of fish diseases. Fish grown in high densities are very vulnerable to viral, bacterial and parasitic infections. Thus, use of preventive measures like vaccination becomes extremely important. Moreover, constant variations in viral strains also contribute to regular disease outbreaks, necessitating continual vaccine development and supply. Emergence of new diseases in fish can offer opportunities for vaccine manufacturers to develop novel therapies. Frequent innovation in vaccine designs along with expansion of vaccine portfolio matching diverse geographies and fish species can drive the market growth over the forecast period.
High Demand for Aquaculture Products
The aquaculture industry has witnessed significant growth over the past few decades to meet rising demand for seafood. Fish farming now accounts for over 50% of the total fish produced for human consumption globally. As fish are raised in high densities on farms, these are more prone to various bacterial and viral diseases. Fish vaccines help prevent outbreaks of these diseases and promote the health and survival of farmed fish. The growth in aquaculture production has led to increased use of fish vaccines, thus, driving the market growth. Many countries and international organizations also support the development and use of fish vaccines to safeguard investments in aquaculture.
Strict Regulations on Antibiotic Use
Authorities worldwide have imposed stringent regulations on the use of antibiotics in aquaculture due to concerns about antibiotic resistance. Previously, antibiotics were widely used in fish farming to treat disease outbreaks. However, their overuse led to the emergence of antibiotic-resistant bacteria. Now, fish farmers are restricted in the types of antibiotics these people can use, and are encouraged to rely more on vaccination programs. This shift away from antibiotics to vaccines is a major factor positively impacting the fish vaccine industry. Vaccines offer a more sustainable solution to control infectious diseases in aquaculture while avoiding development of resistant pathogens.
High Cost of Vaccine Development
Developing new fish vaccine products requires extensive research and clinical trials, which involve significant investments of time and capital. Compared to livestock, fish pathogens are more complex with varying virulence factors among different strains. This complexity challenges researchers in designing broad-spectrum vaccines. The high costs incurred in R&D is passed on to farmers in the form of expensive vaccine prices. These prices often deter small-scale fish farmers in developing nations from regularly vaccinating their stocks. This economic restraint can hamper the market growth, especially in regions with predominantly small farms.
Stringent Efficacy and Safety Testing Standards
Regulatory protocols for approving new fish vaccines are usually very strict to ensure product safety and effectiveness. Vaccines developed for marine species have additional hurdles to cross since these are tested and used in open water net-pen systems rather than controlled terrestrial settings like poultry housing. Lengthy clinical testing leads to longer product development cycles. Manufacturers also must continually upgrade production facilities to meet evolving good manufacturing practice standards. Complying with complex regulations increases costs and delays market entry of novel vaccines. This regulatory barrier deters investments in fish vaccine R&D.
Growing Adoption of Recombinant Vaccine Technologies
Traditional fish vaccines consist of inactivated or attenuated whole pathogens. However, advancements in molecular biology have enabled the development of purified subunit and recombinant vaccines using specific pathogen antigens. These next-gen vaccines provide improved safety, specificity and stability as compared to whole-organism products. Their use is gaining popularity as more recombinant vaccines receive regulatory approvals. Growing popularity of novel vaccine technologies can also drive the market growth. Manufacturers are also exploring advanced delivery vehicles like biodegradable microspheres to enhance vaccine stability and duration of protection.
Rising Global Fish Consumption Increases Demand for Vaccines
Per-capita fish consumption worldwide has steadily increased in both developed and developing countries over the past 50 years. Rising populations and incomes globally can boost demand for fish and other seafood as a vital source of protein. Most experts project that aquaculture production needs to more than double by 2050 to meet escalating seafood demand. This growing market for farmed fish creates significant opportunities for fish vaccine companies. Rising fish production targets incentivize farmers to increase protection of stocks through preventive vaccination programs.
Link: https://www.coherentmarketinsights.com/market-insight/fish-vaccine-market-5184
Key Development
- On January 5, 2024, according to the World Organization for Animal Health, a project in the Philippines is underway to create a vaccine against the Tilapia Lake Virus (TiLV), a newly identified viral pathogen
- In November 2022, Indian Immunologicals (IIL), a veterinary and human biologicals company, partnered with the Central Institute of Freshwater Aquaculture (CIFA),a research institute, to develop a vaccine against hemorrhagic septicemia in freshwater fish. The partnership aims to combat common bacterial diseases in these fish, including Columnaris Disease and Edwardsiellosis. CIFA, under ICAR, will provide the technology for the vaccines.
Key Players: Merck Animal Health (MSD Animal Health), Zoetis, Elanco, Virbac, HIPRA, Veterquímica S.A., Tecnovax, Phibro Animal Health Corporation, Ridgeway Biologicals Ltd., Nisseiken Co., Ltd., Aquatic Animal Health Ltd, Ictyogroup, Benchmark Holdings plc, Vaxxinova, Alpha Biotech Ltd., Vallee S.A., Ringpu Biology, Nippon Zenyaku Kogyo Co., Ltd., Chengdu Tech-bank Biological Products, Weiyuan Gene Tech
